1. Home
  2. COEP vs FGF Comparison

COEP vs FGF Comparison

Compare COEP & FGF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • COEP
  • FGF
  • Stock Information
  • Founded
  • COEP 2017
  • FGF 2012
  • Country
  • COEP United States
  • FGF United States
  • Employees
  • COEP N/A
  • FGF N/A
  • Industry
  • COEP Biotechnology: Biological Products (No Diagnostic Substances)
  • FGF Property-Casualty Insurers
  • Sector
  • COEP Health Care
  • FGF Finance
  • Exchange
  • COEP Nasdaq
  • FGF Nasdaq
  • Market Cap
  • COEP 32.4M
  • FGF 29.0M
  • IPO Year
  • COEP N/A
  • FGF N/A
  • Fundamental
  • Price
  • COEP $10.16
  • FGF $20.92
  • Analyst Decision
  • COEP
  • FGF
  • Analyst Count
  • COEP 0
  • FGF 0
  • Target Price
  • COEP N/A
  • FGF N/A
  • AVG Volume (30 Days)
  • COEP 188.6K
  • FGF 47.5K
  • Earning Date
  • COEP 03-25-2025
  • FGF 03-13-2025
  • Dividend Yield
  • COEP N/A
  • FGF N/A
  • EPS Growth
  • COEP N/A
  • FGF N/A
  • EPS
  • COEP N/A
  • FGF N/A
  • Revenue
  • COEP N/A
  • FGF $22,351,000.00
  • Revenue This Year
  • COEP N/A
  • FGF N/A
  • Revenue Next Year
  • COEP N/A
  • FGF N/A
  • P/E Ratio
  • COEP N/A
  • FGF N/A
  • Revenue Growth
  • COEP N/A
  • FGF N/A
  • 52 Week Low
  • COEP $2.31
  • FGF $14.21
  • 52 Week High
  • COEP $13.70
  • FGF $38.50
  • Technical
  • Relative Strength Index (RSI)
  • COEP 52.25
  • FGF 45.67
  • Support Level
  • COEP $8.65
  • FGF $20.00
  • Resistance Level
  • COEP $13.70
  • FGF $21.40
  • Average True Range (ATR)
  • COEP 1.99
  • FGF 1.64
  • MACD
  • COEP -0.28
  • FGF 0.08
  • Stochastic Oscillator
  • COEP 30.70
  • FGF 35.69

About COEP Coeptis Therapeutics Holdings Inc.

Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.

About FGF FG Financial Group Inc. (NV)

Fundamental Global Inc through its subsidiaries operates as diversified insurance, reinsurance, and investment management holding company. The company's segment includes Insurance and Asset Management. It generates maximum revenue from the Insurance segment.

Share on Social Networks: